Coldstream Capital Management Inc. Increases Position in Bristol-Myers Squibb Co (BMY)

Coldstream Capital Management Inc. boosted its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 8.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,717 shares of the biopharmaceutical company’s stock after acquiring an additional 1,062 shares during the period. Coldstream Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $874,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Renaissance Technologies LLC grew its stake in shares of Bristol-Myers Squibb by 108.5% in the 2nd quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock valued at $751,563,000 after buying an additional 7,020,200 shares during the period. Franklin Resources Inc. grew its stake in shares of Bristol-Myers Squibb by 185.2% in the 2nd quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock valued at $339,830,000 after buying an additional 3,960,191 shares during the period. Jennison Associates LLC grew its stake in shares of Bristol-Myers Squibb by 16.2% in the 3rd quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock valued at $1,711,689,000 after buying an additional 3,735,453 shares during the period. Janus Henderson Group PLC grew its stake in shares of Bristol-Myers Squibb by 2,990.5% in the 2nd quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock valued at $202,494,000 after buying an additional 3,516,536 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its stake in shares of Bristol-Myers Squibb by 42,071.5% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,331,549 shares of the biopharmaceutical company’s stock valued at $185,634,000 after buying an additional 3,323,649 shares during the period. 69.70% of the stock is owned by institutional investors.

Several research firms have recently weighed in on BMY. Vetr cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target for the company. in a research note on Thursday. Piper Jaffray Companies reissued a “hold” rating and issued a $60.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Leerink Swann increased their price target on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a research note on Tuesday. BMO Capital Markets decreased their price objective on shares of Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating on the stock in a report on Tuesday. Finally, Jefferies Group lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price objective on the stock. in a report on Monday, October 16th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $65.58.

In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the sale, the executive vice president now directly owns 9,251 shares in the company, valued at approximately $585,033.24. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Theodore R. Samuels II bought 4,000 shares of Bristol-Myers Squibb stock in a transaction on Friday, December 15th. The shares were acquired at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the acquisition, the director now owns 22,000 shares in the company, valued at $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Co (BMY) opened at $62.63 on Thursday. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Co has a fifty-two week low of $51.12 and a fifty-two week high of $66.10. The company has a market cap of $99,675.04, a P/E ratio of 20.23, a PEG ratio of 1.92 and a beta of 1.09.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping the consensus estimate of $0.67 by $0.01. The firm had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 33.68%. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.63 EPS. research analysts anticipate that Bristol-Myers Squibb Co will post 3.17 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were issued a dividend of $0.40 per share. The ex-dividend date of this dividend was Thursday, January 4th. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a yield of 2.55%. Bristol-Myers Squibb’s dividend payout ratio is 271.19%.

COPYRIGHT VIOLATION NOTICE: “Coldstream Capital Management Inc. Increases Position in Bristol-Myers Squibb Co (BMY)” was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/02/08/coldstream-capital-management-inc-increases-position-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit